Advanced

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

Cornelissen, Jan J.; Gratwohl, Alois; Schlenk, Richard F.; Sierra, Jorge; Bornhaeuser, Martin; Juliusson, Gunnar LU ; Racil, Zdenek; Rowe, Jacob M.; Russell, Nigel and Mohty, Mohamad, et al. (2012) In Nature Reviews Clinical Oncology 9(10). p.579-590
Abstract
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that... (More)
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Reviews Clinical Oncology
volume
9
issue
10
pages
579 - 590
publisher
Nature Publishing Group
external identifiers
  • wos:000309550800010
  • scopus:84867099700
ISSN
1759-4782
DOI
10.1038/nrclinonc.2012.150
language
English
LU publication?
yes
id
e3559261-6d75-4b45-9a5d-4fdfa8c1eb19 (old id 3184309)
date added to LUP
2012-12-03 06:55:06
date last changed
2017-11-12 03:08:31
@article{e3559261-6d75-4b45-9a5d-4fdfa8c1eb19,
  abstract     = {Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.},
  author       = {Cornelissen, Jan J. and Gratwohl, Alois and Schlenk, Richard F. and Sierra, Jorge and Bornhaeuser, Martin and Juliusson, Gunnar and Racil, Zdenek and Rowe, Jacob M. and Russell, Nigel and Mohty, Mohamad and Lowenberg, Bob and Socie, Gerard and Niederwieser, Dietger and Ossenkoppele, Gert J.},
  issn         = {1759-4782},
  language     = {eng},
  number       = {10},
  pages        = {579--590},
  publisher    = {Nature Publishing Group},
  series       = {Nature Reviews Clinical Oncology},
  title        = {The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach},
  url          = {http://dx.doi.org/10.1038/nrclinonc.2012.150},
  volume       = {9},
  year         = {2012},
}